FindTrial
Sign In

To explore the mechanism of the YAP/INF2 signaling pathway mediating oxidative stress in the treatment of obstructive sleep apnea-hypopnea syndrome (OSAHS)

To explore the mechanism of the YAP/INF2 signaling pathway mediating oxidative stress in the treatment of obstructive sleep apnea-hypopnea syndrome (OSAHS)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105265
Enrollment
Unknown
Registered
2025-07-01
Start date
2025-02-12
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive sleep apnea-hypopnea syndrome, OSAHS

Interventions

Standard group of patients with OSAHS:None
Group of patients who did not meet the diagnostic criteria for OSAHS:None

Sponsors

Hangzhou TCM Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Meets the diagnostic criteria for OSAHS; Age between 18 and 70 years old; ?Cooperate with sleep monitoring, serological testing, and other examinations.

Exclusion criteria

Exclusion criteria: Patients with sleep and respiratory disorders caused by other internal diseases such as hypothyroidism, vocal cord paralysis, acromegaly, and other special reasons, as well as those who abuse psychotropic drugs, long-term alcohol abuse, and other serious factors that affect test results; Combine patients with mental disorders, severe cardiovascular and cerebrovascular diseases, liver and kidney dysfunction, or tumors; Individuals who have used antibiotics, probiotics/prebiotics, or immunosuppressants within the past 4 weeks prior to enrollment.

Design outcomes

Primary

MeasureTime frame
HB;CRP;TNF-a;IL-6;IL-4;—

Countries

China

Contacts

Public ContactDuan Hanzhong

Hangzhou TCM Hospital

duanent@163.com+86 189 6997 9606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026